financetom
Business
financetom
/
Business
/
Ukraine's Kyivstar core profit rises 26% driven by digital services
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ukraine's Kyivstar core profit rises 26% driven by digital services
Mar 13, 2026 1:18 AM

March 13 - Ukraine's lead telecom operator Kyivstar ( KYIV )

on Friday reported 2025 core profit up around 26%,

driven by growth in digital sales which now make up 16% of its

total revenue.

Its earnings before interests, taxes, depreciation and

amortization (EBITDA) came in at 648 million USD. Kyivstar ( KYIV ) said

it expected an EBITDA growth of 12% to 15% in 2026.

Digital revenue jumped 467% for the full year to $124

million, boosted largely by the April 2025 acquisition of

ride-hailing platform Uklon, which contributed $80 million in

revenue. In the fourth quarter alone, digital revenue surged

more than sixfold.

"We are transforming Kyivstar ( KYIV ) from a telco service provider

to a digital service provider with a telco license," Chief

Executive Alexander Komarov told Reuters in an interview. He

added that the company's own internally-developed digital

applications grew 120% year-on-year.

Kyivstar ( KYIV ) said Ukraine's first large language model,

currently developed in partnership with Google using the Gemma

open-source framework, has a first version expected in Q2 2026.

A public naming competition is currently underway through the

Diia government app.

The company's total digital monthly active users reached 15

million by year-end, up 41.6% year-on-year, spanning

ride-hailing, healthcare, entertainment and its super-app.

Net profit fell to $124 million from $283 million a year

earlier, weighed down by a one-time non-cash charge of $162

million related to the company's stock market listing. Adjusted

net profit was broadly flat at $286 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
-- JD Bancshares Maintains Dividend at $0.29 Per Share; Payable May 10 to Shareholders of Record May 3
-- JD Bancshares Maintains Dividend at $0.29 Per Share; Payable May 10 to Shareholders of Record May 3
Apr 24, 2024
03:11 PM EDT, 04/24/2024 (MT Newswires) -- Price: 22.03, Change: +2.42, Percent Change: +12.34 ...
US OKs sale of missiles to Poland and the Netherlands for $2 bln
US OKs sale of missiles to Poland and the Netherlands for $2 bln
Apr 24, 2024
WASHINGTON, April 24 (Reuters) - The U.S. State Department has approved the potential sale of advanced anti-radiation guided missiles with an extended range to Poland for about $1.3 billion and to the Netherlands for about $700 million, the Pentagon said on Wednesday. The principal contractor for both will be Northrop Grumman ( NOC ) , according to the Pentagon. ...
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug
Apr 24, 2024
03:21 PM EDT, 04/24/2024 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Wednesday the US Food and Drug Administration granted another Type-B meeting in Q2 to move ahead with the biologics license application for CAP-1002 for treating Duchenne muscular dystrophy. The company said it will share safety and efficacy data from the open-label extension study with the FDA in...
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise
Apr 24, 2024
03:25 PM EDT, 04/24/2024 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) rallied Wednesday after the US Food and Drug Administration approved its generic version of the nasal spray used to treat opioid overdose. Amneal's Naloxone HCI nasal spray is the generic version of OTC Narcan HCI nasal spray. Emergent BioSolutions ( EBS ) owns the trademark. AMRX shares were...
Copyright 2023-2026 - www.financetom.com All Rights Reserved